Fujifilm Diosynth announced plans to build a research center in the UK to answer growing demand in services for biologics, vaccines, and gene therapies development.
Lonza partners with three research organizations to transfer their preclinical immunotherapies development projects into the Cocoon closed automated processing platform.
Frontage has announced completion of its Pennsylvania site expansion to boost its offering of bioanalytical services for late-stage cell and gene therapies developers.
After posting revenue growth of 39%, Repligen CEO suggests this was driven by filtration and chromatography franchises, particularly customers in gene therapy.
In its latest deal, BIA Separations brings to market an elution method developed by the University of Zagreb, which helps preserve viruses’ integrity, infectivity, and potency.
Funding from Gamma supports the development of Univercells’ biomanufacturing platform and bioreactors, with the latter looking to expand into the fast-growing gene therapy segment.
Aiming to improve flexibility in bioprocessing, Eppendorf launches SciVario twin, a bioreactor control system enabling remote monitoring of microbial and cell culture processes.
The newly separate business will include women’s health, legacy brands, and biosimilar units, as the main part of the business retains oncology, vaccines, hospital and animal health.
Vineti’s latest financing round sees Novartis and Gilead join forces to invest in technology platform that enables scale-up of CAR Ts and allogeneic cell therapies.
The Alliance for Regenerative Medicine publishes a cross-border healthcare plan, which would enable ‘timely and effective’ access to ATMPs for patients in Europe.
Capital expenditure is rising across the pharma industry as portfolios and pipelines shift towards biologics, but the largest companies are sticking to in-house production.
GE Healthcare reacts to the number of regenerative medicine companies operating globally by announcing plans for a facility to create single-use kits and advanced therapies.
Year-on-year, the number of trials for advanced therapeutics has doubled, meaning that the UK now represents 12% of all global clinical trials in the area.
The newly established deal includes the co-development of up to three T-cell therapies, by utilizing the latter’s stem-cell derived allogeneic T-cell platform.
With the number of roles in manufacturing projected to rise by 196% over the next five years, industry fears a lack of expertise to fill vacuum, according to survey.
Biosana to work collaboratively with the Bioprocessing Technology Institute, aiming to design a highly flexible and cost-effective continuous manufacturing solution.
ACG Inspection’s CEO talks about a ‘fear’ of the disruption caused by advanced medicine, which prevents big pharma companies from investing in the supply chain.
GE Healthcare tops its C-Pro cell processing system with SpinOculation, an automation software that enables closed T cells transduction at the preferred volume and concentration.
